DIME PROJECT

DECODE-CRS: Accelerating safer, scalable immunotherapy

Cytokine release syndrome (CRS) remains one of the greatest barriers to realizing the full potential of immunotherapy. The risk of severe CRS inflates development costs, complicates regulatory approvals, and prevents broader adoption, especially in community settings. This toxicity results in limited patient access, slowed innovation, and significant commercial risk for developers.

DECODE-CRS, led by DiMe and Ametris, is the first industry-wide effort to solve this challenge head-on. By pooling expertise, data, and resources, we are building the foundation for clinically appropriate, regulatory-acceptable, and commercially viable CRS de-risking products.

Are you ready to join?

As a partner, you can:

De-risk your pipeline: Access insights by participating in one of the largest prospective datasets on CRS, built across multiple modalities, therapies, and indications.

Future-proof your regulatory submissions: Participate in a dialogue that builds on DATAcc by DiMe’s previous CRS de-risking work in collaboration with the FDA.

Shape the future of CRS measurement and management: Influence clinical and research direction by contributing to consensus on how to define, collect, and adjudicate CRS measures.

Accelerate market adoption: Gain a seat at the table with payors, providers, and health systems to align on feasibility, reimbursement, and workflow integration.

Position your brand as a leader: Demonstrate commitment to patient safety, innovation, and access by being a partner with the first consortium tackling CRS at scale.

Joining DECODE-CRS means you’re not just supporting the work. You’ll be shaping it. Project partners will influence the design, testing, and validation of solutions that could fundamentally change how immunotherapies are developed, monitored, and delivered.

Building with experience

DECODE-CRS builds directly on the foundation established by DATAcc by DiMe’s CRS de-risking project, where we worked with regulators, biopharma, clinicians, and patients to define the key input signals and strategic roadmap for early CRS prediction.

Join us